Categories Earnings, Health Care

Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot

— Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected.

— Revenues grew 13% to $2.17 billion, vs. $2.11 billion expected.

Regeneron reports Q4 2019 earnings results

— Net product sales were $1.28 billion.

— EYLEA net product sales in the US were $1.22 billion.

— Sanofi and Bayer collaboration revenues were $748 million.

— R&D expenses totaled $683 million.

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Salesforce stock hit by weak guidance, co-CEO’s exit. What next?

For technology stocks, 2022 has been a challenging year, with companies losing significant market value amid prolonged stock selloff. In that respect, Salesforce, Inc. (NYSE: CRM) is among the worst-affected

Macy’s (M): Here’s a look at the retailer’s expectations for the near term

Shares of Macy’s Inc. (NYSE: M) were down on Thursday. The stock has gained 36% over the past three months and 18% over the past one month. The company’s sales

KR Earnings: Kroger Q3 sales, profit increase and top expectations

Department store chain The Kroger Co. (NYSE: KR) on Thursday said its third-quarter sales and adjusted earnings increased year-over-year. The latest numbers also exceeded the market's expectations. Net earnings attributable to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top